{
  "schema_version": 1,
  "kind": "drug_profile",
  "generic": "clonazepam",
  "review_status": "reviewed",
  "origin": "openfda",
  "sections": {
    "adult": [
      {
        "text": "Adults : The initial dose for adults with seizure disorders should not exceed 1.5 mg/day divided into three doses.",
        "source": "US FDA label for clonazepam (Clonazepam), section 'dosage and administration', retrieved 2026-08-29",
        "cached_file": "labels/clonazepam.json",
        "verbatim": true
      },
      {
        "text": "Dosage may be increased in increments of 0.5 to 1 mg every 3 days until seizures are adequately controlled or until side effects preclude any further increase.",
        "source": "US FDA label for clonazepam (Clonazepam), section 'dosage and administration', retrieved 2026-08-29",
        "cached_file": "labels/clonazepam.json",
        "verbatim": true
      },
      {
        "text": "Maximum recommended daily dose is 20 mg.",
        "source": "US FDA label for clonazepam (Clonazepam), section 'dosage and administration', retrieved 2026-08-29",
        "cached_file": "labels/clonazepam.json",
        "verbatim": true
      }
    ],
    "child": [
      {
        "text": "Because of the possibility that adverse effects on physical or mental development could become apparent only after many years, a benefit-risk consideration of the long-term use of clonazepam is important in pediatric patients being treated for seizure disorder (see INDICATIONS AND USAGE and DOSAGE AND ADMINISTRATION ). Safety and effectiveness in pediatric patients with panic disorder below the age of 18 have not been established.",
        "source": "US FDA label for clonazepam (Clonazepam), section 'pediatric use', retrieved 2026-08-29",
        "cached_file": "labels/clonazepam.json",
        "verbatim": true
      },
      {
        "text": "Pediatric Patients: Clonazepam is administered orally. In order to minimize drowsiness, the initial dose for infants and children (up to 10 years of age or 30 kg of body weight) should be between 0.01 and 0.03 mg/kg/day but not to exceed 0.05 mg/kg/day given in two or three divided doses.",
        "source": "US FDA label for clonazepam (Clonazepam), section 'pediatric use', retrieved 2026-08-29",
        "cached_file": "labels/clonazepam.json",
        "verbatim": true
      },
      {
        "text": "Pediatric Patients: There is no clinical trial experience with clonazepam in panic disorder patients under 18 years of age.",
        "source": "US FDA label for clonazepam (Clonazepam), section 'pediatric use', retrieved 2026-08-29",
        "cached_file": "labels/clonazepam.json",
        "verbatim": true
      }
    ],
    "renal": [
      {
        "text": "No kidney-impairment dose in this label. Not a statement that none is needed.",
        "source": "Read and found silent: the US FDA label for clonazepam (Clonazepam), retrieved 2026-08-29",
        "cached_file": "labels/clonazepam.json",
        "verbatim": false
      }
    ],
    "hepatic": [
      {
        "text": "No liver-impairment dose in this label. Not a statement that none is needed.",
        "source": "Read and found silent: the US FDA label for clonazepam (Clonazepam), retrieved 2026-08-29",
        "cached_file": "labels/clonazepam.json",
        "verbatim": false
      }
    ],
    "pregnancy": [
      {
        "text": "Advise pregnant females that use of clonazepam late in pregnancy can result in sedation (respiratory depression, lethargy, hypotonia) and/or withdrawal symptoms (hyperreflexia, irritability, restlessness, tremors, inconsolable crying, and feeding difficulties) in newborns (see WARNINGS: Neonatal Sedation and Withdrawal Syndrome and PRECAUTIONS: Pregnancy ).",
        "source": "US FDA label for clonazepam (Clonazepam), section 'pregnancy', retrieved 2026-08-29",
        "cached_file": "labels/clonazepam.json",
        "verbatim": true
      },
      {
        "text": "Instruct patients to inform their healthcare provider if they are pregnant.",
        "source": "US FDA label for clonazepam (Clonazepam), section 'pregnancy', retrieved 2026-08-29",
        "cached_file": "labels/clonazepam.json",
        "verbatim": true
      },
      {
        "text": "Encourage patients to enroll in the North American Antiepileptic Drug (NAAED) Pregnancy Registry if they become pregnant while taking clonazepam.",
        "source": "US FDA label for clonazepam (Clonazepam), section 'pregnancy', retrieved 2026-08-29",
        "cached_file": "labels/clonazepam.json",
        "verbatim": true
      }
    ],
    "lactation": [
      {
        "text": "Nursing: Instruct patients to inform their healthcare provider if they are breastfeeding or intend to breastfeed.",
        "source": "US FDA label for clonazepam (Clonazepam), section 'nursing mothers', retrieved 2026-08-29",
        "cached_file": "labels/clonazepam.json",
        "verbatim": true
      },
      {
        "text": "Instruct breastfeeding patients who take clonazepam to monitor their infants for excessive sedation, poor feeding and poor weight gain, and to seek medical attention if they notice these signs (see PRECAUTIONS: Nursing Mothers ).",
        "source": "US FDA label for clonazepam (Clonazepam), section 'nursing mothers', retrieved 2026-08-29",
        "cached_file": "labels/clonazepam.json",
        "verbatim": true
      },
      {
        "text": "Risk Summary Clonazepam is excreted in human milk.",
        "source": "US FDA label for clonazepam (Clonazepam), section 'nursing mothers', retrieved 2026-08-29",
        "cached_file": "labels/clonazepam.json",
        "verbatim": true
      }
    ]
  }
}